Last Updated: May 17, 2024
challengeduchenne.com has 4 NS records, 2 A records, 2 AAAA records, 0 MX records, and 1 TXT records. Name servers for challengeduchenne.com are ns1.p201.dns.oraclecloud.net, ns3.p201.dns.oraclecloud.net, ns2.p201.dns.oraclecloud.net, ns4.p201.dns.oraclecloud.net. A records for challengeduchenne.com are 104.18.33.249, 172.64.154.7. AAAA records for challengeduchenne.com are 2606:4700:4400:0:0:0:6812:21f9, 2606:4700:4400:0:0:0:ac40:9a07. We have observed challengeduchenne.com to have 2 subdomains. A subdomain count of 2 is considered a small digital footprint. Technology that may be in use at challengeduchenne.com includes google. The domain's primary website is hosted on a CloudFront web server at 13.226.225.106 in United States. The website's description is: "in the treatment of duchenne muscular dystrophy (dmd), gene therapy may provide a new direction. pfizer's gene transfer therapy is in clinical trials & is not fda approved."
Search DigitalStakeout Footprint to find another asset.
104.18.33.249
172.64.154.7
2606:4700:4400:0:0:0:6812:21f9
2606:4700:4400:0:0:0:ac40:9a07
No DNS MX records
ns1.p201.dns.oraclecloud.net
ns3.p201.dns.oraclecloud.net
ns2.p201.dns.oraclecloud.net
ns4.p201.dns.oraclecloud.net
challengeduchenne.com. 1800 IN TXT "google-site-verification=i8bGMOCXVieE2zgzppm8ZjjoomksP0i5tj5sKxN8Lnc"
challengeduchenne.com has 2 subdomains in our inventory.
CloudFront
13.226.225.106
United States
dpl:page:pagesource: pfizer
dpl:page:contentorigin: original
dpl:page:brand: abdec
dpl:page:indication: acid reflux
og:title: home page | challenge duchenne for hcps
og:description: in the treatment of duchenne muscular dystrophy (dmd), gene therapy may provide a new direction. pfizer's gene transfer therapy is in clinical trials & is not fda approved.
og:url: https://www.challengeduchenne.com
og:type: website
twitter:title: home page | challenge duchenne for hcps
twitter:description: in the treatment of duchenne muscular dystrophy (dmd), gene therapy may provide a new direction. pfizer's gene transfer therapy is in clinical trials & is not fda approved.
twitter:url: https://www.challengeduchenne.com
twitter:card: summary
{"message_type": "certificate_update", "data": {"leaf_cert": {"not_after": 1703523483, "signature_algorithm": "sha384, ecdsa", "extensions": {"subjectKeyIdentifier": "03:49:B7:E7:0E:73:6A:3B:A6:FB:33:F1:6D:27:C9:53:3E:7E:05:A9", "authorityKeyIdentifier": "keyid:5A:F3:ED:2B:FC:36:C2:37:79:B9:52:30:EA:54:6F:CF:55:CB:2E:AC\n", "extendedKeyUsage": "TLS Web server authentication, TLS Web client authentication", "subjectAltName": "DNS:challengeduchenne.com", "keyUsage": "Digital Signature", "certificatePolicies": "Policy: 2.23.140.1.2.1", "ctlPoisonByte": true, "authorityInfoAccess": "CA Issuers - URI:http://e1.i.lencr.org/\nOCSP - URI:http://e1.o.lencr.org\n", "basicConstraints": "CA:FALSE"}, "fingerprint": "FF:34:8D:C6:48:ED:20:50:2D:90:4E:FE:1F:5E:04:C7:54:01:11:03", "all_domains": ["challengeduchenne.com"], "serial_number": "36CABD4CC53566E92FE05DDB969796EFFF9", "subject": {"C": null, "CN": "challengeduchenne.com", "L": null, "O": null, "ST": null, "emailAddress": null, "OU": null, "aggregated": "/CN=challengeduchenne.com"}, "not_before": 1695747484, "issuer": {"C": "US", "CN": "E1", "L": null, "O": "Let's Encrypt", "ST": null, "emailAddress": null, "OU": null, "aggregated": "/C=US/CN=E1/O=Let's Encrypt"}}, "cert_link": "https://ct.googleapis.com/logs/xenon2023/ct/v1/get-entries?start=2008839435&end=2008839435", "source": {"url": "https://ct.googleapis.com/logs/xenon2023/", "name": "Google 'Xenon2023' log"}, "update_type": "PrecertLogEntry", "seen": 1695751178.963446, "cert_index": 2008839435}}